Trial Profile

A First-in-Human Phase I Study of ATG-031 in Patients With Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATG 031 (Primary)
Indications Advanced breast cancer; B-cell lymphoma; Liver cancer; Lung cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man
Acronyms PERFORM
Sponsors Antengene Corporation

Most Recent Events

09 Jun 2025 All the dose levels beyond 1.0 mg/kg are replaced by 0.5 mg/kg, or other dose level less than 1.0 mg/kg. Planned enrollment is increased.
09 Jun 2025 Planned number of patients changed from 48 to 80.
09 Jun 2025 Planned End Date changed from 30 Jun 2026 to 30 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com